How have CYTK and IMVT total returns compared?

Over the past 5 years, CYTK delivered 11.24% and IMVT delivered 29.93% annualized total return. Past performance doesn't predict future results.

Cytokinetics, Incorporated (CYTK) vs Immunovant, Inc. (IMVT)

A side-by-side comparison of Cytokinetics, Incorporated and Immunovant, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CYTK

Cytokinetics, Incorporated

$7.70B

$61.84HealthcareDelayed quote: Oct 6, 2026, 9:40 AM EDT

IMVT

Immunovant, Inc.

$6.84B

$33.15HealthcareDelayed quote: Oct 6, 2026, 9:40 AM EDT

Total return — CYTK vs IMVT

growth of $100 · dividends reinvested · last 7y

CYTK +462.8% (+28.0%/yr)IMVT +234.2% (+18.8%/yr)CYTK compounded faster over this window

CYTK IMVT

CYTK vs IMVT: by the numbers

•CYTK is the larger company ($7.70B vs $6.84B market cap).
•Both run net losses; CYTK's is the smaller (-1259.87% vs -7585.86% net margin).

Metrics side by side

Valuation

Metric	CYTK	IMVT
P/S ratio	108.44	964.37
P/B ratio	N/A	9.30

Profitability

Metric	CYTK	IMVT
Gross margin	84.97%	0.00%
Operating margin	-695.44%	0.00%
Net margin	-1259.87%	-7585.86%
ROE	N/A	-73.19%
ROIC	-39.80%	-76.00%

Growth (annualized)

Metric	CYTK	IMVT
Revenue CAGR (5Y)	4.19%	N/A
Total return CAGR (5Y)	11.24%	29.93%

Frequently asked

How have CYTK and IMVT total returns compared?: Over the past 5 years, CYTK delivered 11.24% and IMVT delivered 29.93% annualized total return. Past performance doesn't predict future results.

Go deeper

Full CYTK analysis Full IMVT analysis Interactive comparison tool

Dig into the metrics

Cytokinetics ROE Immunovant ROE Cytokinetics operating margin Immunovant operating margin Cytokinetics revenue growth Immunovant revenue growth Cytokinetics free cash flow Immunovant free cash flow

Cytokinetics & Immunovant appear in these rankings

Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.